Morria Biopharmaceuticals

Morria Biopharmaceuticals engages in the discovery and development of multi-functional anti-inflammatory drugs.

Morria Biopharmaceuticals Plc, a biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs. The company’s products in Phase 2a clinical pipeline include MRX-4, a nasal spray for treating allergic rhinitis or hay fever, as well as MRX-6, a topical cream for treating contact dermatitis, a common type of eczema. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis and dry eye; MRX-5 used in the treatment of inflammatory bowel disease; and CFX-1 for the treatment of cystic fibrosis. The company is headquartered in London, the United Kingdom.